Standard Drug Tx as Good as Stem Cell Transplant for Scleroderma?
Patients who underwent autologous stem cell transplantation (ASCT) for diffuse cutaneous systemic sclerosis (dcSSc), also known as scleroderma, did no better than others receiving conventional treatment, researchers found. In an analysis of systemic sclerosis patients enrolled in an Australian cohort study, those who would have been eligible for ASCT in either of two clinical trials […]
ASCT Tops CAR T-Cell Therapy for Relapsed LBCL in Complete Remission
SAN DIEGO — Autologous stem-cell transplantation (ASCT) led to improved outcomes as compared with CAR T-cell therapy for patients with relapsed large B-cell lymphoma (LBCL) in complete remission, a retrospective analysis showed. Patients who underwent ASCT had fewer relapses at 2 years (27.8% vs 48.0%) and better progression-free survival (PFS, 66.2% vs 47.8%), and overall […]
Standard Lymphoma Therapies Tied to Higher Risk for New Malignancies
Use of high-dose chemotherapy and autologous hematopoietic stem-cell transplantation (HSCT) for patients with aggressive lymphoma was associated with an increased risk of certain second primary malignancies (SPMs), according to a retrospective Danish population-based cohort study. The overall SPM rate was higher among lymphoma patients compared with matched controls from the general population (HR 2.35, 95% […]
Rigid In-Hospital Diet Offers No Advantage in Patients After HSCT
NEW ORLEANS — Patients who have neutropenia after undergoing hematopoietic stem cell transplantation (HSCT) do not need to restrict themselves to unpalatable hospital foods, a researcher said here. A randomized study of over 200 patients with hematologic diseases showed that patients who received a non-restrictive diet — including fresh fruits and vegetables, cold cuts, and […]
New Evidence Sheds Light on Stem Cell Transplantation for Progressive MS
Autologous hematopoietic stem cell transplantation (AHSCT) was not superior in preventing relapses or reducing disability progression than natalizumab (Tysabri) in progressive multiple sclerosis (MS), new research suggested. Patients with progressive MS, advanced disability, and low pre-treatment relapse activity who had AHSCT experienced similar on-treatment frequency of relapses as matched patients treated with natalizumab over up […]
How Did the COVID Pandemic Affect Liver Transplant Outcomes?
The COVID-19 pandemic had a substantial impact on liver transplantation outcomes, with lower graft survival and patient survival at 90 days post-transplant versus a pre-pandemic time period, a researcher said. Graft survival was significantly lower during the COVID versus pre-COVID period (95.2% vs 96.0%) and there was a significant decline in patient survival (96.0% vs […]